Blood Pressure Medication Recall: Inventia Recalls 13,000 Bottles of Chlorthalidone
2 min read
The FDA has classified a nationwide voluntary recall of 25 mg hypertension tablets over dissolution test failures that may reduce medication effectiveness.
⚡ Key Takeaways
- Inventia Healthcare initiated a voluntary recall of 13,567 bottles of 25 mg Chlorthalidone tablets.
- The medication failed laboratory dissolution testing, meaning tablets may not absorb properly in the body.
- Physicians stress that patients should consult their pharmacist before discontinuing blood pressure therapy.
Millions of Americans rely on daily hypertension medications to regulate cardiovascular health, making pharmaceutical quality control paramount. The Food and Drug Administration has confirmed a nationwide Class II recall affecting thousands of bottles of Chlorthalidone tablets.
Why the Medication Failed Quality Specifications
The voluntary recall covers 13,567 bottles of 25 mg Chlorthalidone distributed across retail and hospital pharmacies nationwide. Routine post-manufacturing stability audits revealed that the tablets failed established dissolution parameters.
When a pill fails dissolution criteria, it does not dissolve at the expected speed in the digestive tract. Consequently, the active pharmacological compound may not be adequately absorbed, reducing its therapeutic efficacy in lowering high blood pressure.
Understanding the FDA’s Class II Status
The FDA categorized the action as a Class II recall, a regulatory tier reserved for situations where a product may cause temporary, medically reversible health consequences, but the chance of severe harm remains low.
This marks the second packaging alert for the manufacturer this year following an earlier batch notice in June. Regulators noted that no serious clinical adverse events have been directly linked to the current batch to date.
Impacted Lot: Batch Number RISA24002 (100-count bottles with an expiration date of April 2027).
Classification: FDA Class II Recall—the likelihood of serious adverse health consequences is considered remote.
Clinical Advice: Abruptly stopping antihypertensives can cause dangerous blood pressure spikes; contact your prescriber for an alternative batch.
What Patients and Caregivers Should Do Now
Health authorities strongly advise consumers not to panic or immediately stop taking their daily dose without professional consultation. Suddenly withholding antihypertensive drugs can trigger rebound hypertension and cardiovascular stress.
Patients should inspect their prescription bottle for batch number RISA24002 and call their dispensing pharmacy. Pharmacists are equipped to provide immediate replacements from unaffected manufacturing lots at no additional cost.
You May Also Like
Mountain Dew Pitch Black Returns: Cult Citrus-Grape Flavor Relaunches for Halloween 2026
The legendary dark-hued soda that sparked beverage turf wars is making a triumphant autumn comeback, hitting retail shelves just in time for spooky season. Few limited-edition sodas in beverage history command the fanatical loyalty of Mountain Dew Pitch Black. First introduced more than twenty years ago as a spooky Halloween exclusive, the deep-purple nectar has […]
Urgent Food Recalls: FDA and USDA Issue Consumer Alerts for Cheese, Meat, and Sausage
Federal health inspectors warn shoppers to check kitchen pantries and refrigerators as potential E. coli and foreign material risks trigger multi-state product recalls. Federal health regulators have issued a slate of urgent food safety warnings, prompting nationwide grocery shoppers to inspect their refrigerators and freezers for potentially contaminated dairy, pork, and specialty meat products. Key […]
What Is an Aerocano? The Steam-Frothed Iced Espresso Trend Explained
Baristas and home coffee lovers are using espresso steam wands on cold brew to create a silky, dairy-free foam that rivals draft nitro coffee.